Elisabetta Hitchman
About Elisabetta Hitchman
Elisabetta Hitchman is a Group Leader in Vector Process Development at Adaptimmune, where she has worked since 2020. She has a background in process development and research, having held positions at Oxford Brookes University, Oxford BioMedica, and Oxford Expression Technologies.
Current Role at Adaptimmune
Elisabetta Hitchman serves as the Group Leader for Vector Process Development at Adaptimmune. She has held this position since 2020, contributing to advancements in vector technologies within the organization. Her role involves overseeing the development of processes that support the production of viral vectors, which are essential for therapeutic applications in immunotherapy.
Previous Experience at Adaptimmune
Before her current role, Elisabetta Hitchman worked at Adaptimmune as an Upstream Process Development Senior Scientist from 2018 to 2020. In this capacity, she focused on optimizing upstream processes to enhance the efficiency and yield of vector production, playing a key role in the organization's research and development efforts.
Academic Background at Oxford Brookes University
Elisabetta Hitchman completed her PhD at Oxford Brookes University from 2010 to 2014. During her time as a PhD student, she engaged in research that contributed to her expertise in bioprocessing and vector development, laying the foundation for her future roles in the biotechnology sector.
Experience at Oxford BioMedica
Prior to her tenure at Adaptimmune, Elisabetta Hitchman worked at Oxford BioMedica as a Scientist from 2015 to 2018. In this role, she focused on the development and optimization of viral vector production processes, contributing to the company's mission of advancing gene and cell therapies.
Early Career at Oxford Expression Technologies
Elisabetta Hitchman began her career as a Research Assistant at Oxford Expression Technologies from 2009 to 2010. This position provided her with foundational experience in molecular biology techniques and vector design, which has been integral to her subsequent roles in the biotechnology field.